Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247462 | 0.87 | PPARG (0.38) | PPARAPPARGEPHX2EPHX1NR1H4 | |
| SCHEMBL8272997 | 0.87 | PPARG (0.38) | PPARAPPARGEPHX2EPHX1NR1H4 | |
| SCHEMBL27659006 | 0.86 | EPHX2 (0.37) | PPARAPPARGEPHX2ACACBEPHX1 | |
| SCHEMBL1825297 | 0.86 | EPHX2 (0.37) | PPARAPPARGEPHX2ACACBEPHX1 | |
| SCHEMBL13038891 | 0.85 | EPHX2 (0.36) | PPARAPPARGEPHX2ACACBPTPN1 | |
| SCHEMBL8271393 | 0.82 | CYP1A2 (0.40) | — | |
| SCHEMBL3876908 | 0.80 | CHRM4 (0.46) | — | |
| SCHEMBL2249003 | 0.80 | CHRM4 (0.46) | — | |
| SCHEMBL2550208 | 0.80 | CHRM4 (0.46) | — | |
| SCHEMBL27659011 | 0.78 | HSD11B1 (0.37) | GLAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660471-B1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1660471-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019194-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LIMITED (GB) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | MMP13, MMP3, MMP1 | PPARA 2415/4885PPARG 2270/4885EPHX2 336/4885 |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | MMP3, MMP1, MMP13 | PPARA 1487/4885PPARG 1204/4885EPHX2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.